Shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) have been given a consensus rating of “Moderate Buy” by the twenty-seven analysts that are covering the stock, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a hold recommendation, fifteen have given a buy recommendation and three have given a strong buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $110.55.
A number of equities research analysts have issued reports on GILD shares. Cantor Fitzgerald started coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 target price for the company. Oppenheimer reduced their price objective on Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, April 25th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a research report on Thursday, March 27th. Finally, Morgan Stanley increased their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research report on Friday, April 25th.
Get Our Latest Research Report on Gilead Sciences
Gilead Sciences Stock Down 0.2%
Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to analysts’ expectations of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The company’s revenue was down .3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.32) earnings per share. Equities analysts expect that Gilead Sciences will post 7.95 earnings per share for the current year.
Gilead Sciences Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were given a $0.79 dividend. The ex-dividend date was Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.84%. Gilead Sciences’s dividend payout ratio (DPR) is currently 66.53%.
Insider Buying and Selling
In related news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the transaction, the insider directly owned 121,152 shares of the company’s stock, valued at $13,026,263.04. This trade represents a 18.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $110.17, for a total value of $275,425.00. Following the completion of the transaction, the chief financial officer directly owned 165,110 shares of the company’s stock, valued at approximately $18,190,168.70. This trade represents a 1.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 58,500 shares of company stock valued at $6,340,745 over the last ninety days. 0.27% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of GILD. Redwood Financial Network Corp raised its position in Gilead Sciences by 4.0% in the fourth quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 98 shares during the last quarter. Argentarii LLC raised its position in Gilead Sciences by 3.0% in the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock valued at $380,000 after purchasing an additional 99 shares during the last quarter. Nicolet Advisory Services LLC raised its position in Gilead Sciences by 2.9% in the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company’s stock valued at $322,000 after purchasing an additional 100 shares during the last quarter. Peak Financial Advisors LLC raised its position in Gilead Sciences by 1.7% in the first quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company’s stock valued at $677,000 after purchasing an additional 100 shares during the last quarter. Finally, Perkins Coie Trust Co raised its position in Gilead Sciences by 2.6% in the first quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company’s stock valued at $435,000 after purchasing an additional 100 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Recommended Stories
- Five stocks we like better than Gilead Sciences
- When to Sell a Stock for Profit or Loss
- 3 Defense Leaders Set to Gain From Rising Military Spend
- 5 Top Rated Dividend Stocks to Consider
- Why the Schwab Dividend ETF Rallied—and Can It Keep Climbing?
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- MarketBeat Week in Review – 06/30 – 07/04
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.